Report - ASPEN-01: A Phase 1 Study of ALX148, a CD47 Blocker, in ......(EVAL) ORR (%) [95% CI] DOR (m) [95% CI] PFS (m) [95% CI] PFS Rate at 6 m OS (m) [95% CI] OS Rate at 12 m Follow Up (m)

Select PornographicDefamatoryIllegal/UnlawfulSpamOther Terms Of Service ViolationFile a copyright complaint

Please pass captcha verification before submit form